Neurochemical Research

, Volume 37, Issue 7, pp 1534–1544 | Cite as

In Vivo Electroporation of a New Gene Vaccine Encoding Ten Repeats of Aβ3-10 Prevents Brain Aβ Deposition and Delays Cognitive Impairment in Young Tg-APPswe/PSEN1dE9 Mice

  • Sha Sha
  • Xiao-Na Xing
  • Wan-Shu Guo
  • Yu Li
  • Li-Xia Zong
  • Rong Guo
  • Yun-Peng Cao
Original Paper


Active immunization holds great promise for the treatment of Alzheimer’s disease but the infiltration of T-lymphocytes and associated meningoencephalitis observed in clinical trials needs to be overcome. To avoid this toxicity, previous studies have used synthetic truncated derivatives of Aβ to promote humoral immunity. In this study, we developed a novel vaccine [p(Aβ3-10)10-MT] that expresses ten repeats of Aβ3-10 with melatonin (MT) as an adjuvant, and administered it intramuscularly in three-month-old Tg-APPswe/PSEN1dE9 (Tg) mice by in vivo electroporation. The p(Aβ3-10)10-MT vaccine induced high titers of anti-Aβ antibodies, which in turn reduced Aβ deposits in the mouse brains and decreased cognitive impairment. Immunoglobulin isotyping revealed a predominantly IgG1 response, indicating a Th2 anti-inflammatory response. Ex vivo cultured splenocytes exhibited a low IFN-γ and high IL-4 response. Immunohistochemical analysis revealed that glial cell activation was also attenuated. These results indicate that p(Aβ3-10)10-MT may potentially be an effective vaccine to reduce accumulated Aβ and attenuate cognitive deficits.


Alzheimer’s disease Gene vaccine Amyloid β-protein In vivo electroporation 



This study was supported by a National Nature Science Foundation of China grant, number 30471927.


  1. 1.
    Hardy JA, Higgins GA (1992) Alzheimer’s disease: the amyloid cascade hypothesis. Science 256:184–185PubMedCrossRefGoogle Scholar
  2. 2.
    Hardy J, Selkoe DJ (2002) The amyloid hypothesis of Alzheimer’s disease: progress and problems on the road to therapeutics. Science 297:353–356PubMedCrossRefGoogle Scholar
  3. 3.
    Dodart JC, Bales KR, Gannon KS et al (2002) Immunization reduces memory deficits without reducing brain Abeta burden in Alzheimer’s disease model. Nat Neurosci 5:452–457PubMedGoogle Scholar
  4. 4.
    Rosenberg RN (2005) Immunotherapy for Alzheimer disease: the promise and the problem. Arch Neurol 62:1506–1507PubMedCrossRefGoogle Scholar
  5. 5.
    Ferrer I, Boada Rovira M, Sánchez Guerra ML et al (2004) Neuropathology and pathogenesis of encephalitis following amyloid-beta immunization in Alzheimer’s disease. Brain Pathol 14:11–20PubMedCrossRefGoogle Scholar
  6. 6.
    Patton RL, Kalback WM, Esh CL et al (2006) Amyloid-beta peptide remnants in AN-1792-immunized Alzheimer’s disease patients: a biochemical analysis. Am J Pathol 169:1048–1063PubMedCrossRefGoogle Scholar
  7. 7.
    Cribbs DH (2010) Abeta DNA vaccination for Alzheimer’s disease: focus on disease prevention. CNS Neurol Disord: Drug Targets 9:207–216Google Scholar
  8. 8.
    Wiessner C, Wiederhold KH, Tissot AC et al (2011) The second-generation active A{beta} immunotherapy CAD106 reduces amyloid accumulation in APP transgenic mice while minimizing potential side effects. J Neurosci 31:9323–9331PubMedCrossRefGoogle Scholar
  9. 9.
    Qu B, Rosenberg RN, Li L et al (2004) Gene vaccination to bias the immune response to amyloid-beta peptide as therapy for Alzheimer disease. Arch Neurol 61:1859–1864PubMedCrossRefGoogle Scholar
  10. 10.
    Qu BX, Xiang Q, Li L et al (2007) Abeta42 gene vaccine prevents Abeta42 deposition in brain of double transgenic mice. J Neurol Sci 260:204–213PubMedCrossRefGoogle Scholar
  11. 11.
    Agadjanyan MG, Ghochikyan A, Petrushina I et al (2005) Prototype Alzheimer’s disease vaccine using the immunodominant B cell epitope from beta-amyloid and promiscuous T cell epitope pan HLA DR-binding peptide. J Immunol 174:1580–1586PubMedGoogle Scholar
  12. 12.
    Ghochikyan A, Mkrtichyan M, Petrushina I et al (2006) Prototype Alzheimer’s disease epitope vaccine induced strong Th2-type anti-Ab antibody response with Alum to Quil A adjuvant switch. Vaccine 24:2275–2282PubMedCrossRefGoogle Scholar
  13. 13.
    Monsonego A, Maron R, Zota V et al (2001) Immune hyporesponsiveness to amyloid beta-peptide in amyloid precursor protein transgenic mice: implications for the pathogenesis and treatment of Alzheimer’s disease. Proc Natl Acad Sci U S A 98:10273–10278PubMedCrossRefGoogle Scholar
  14. 14.
    Seabrook TJ, Thomas K, Jiang L et al (2007) Dendrimeric Abeta1–15 is an effective immunogen in wildtype and APP-tg mice. Neurobiol Aging 28:813–823PubMedCrossRefGoogle Scholar
  15. 15.
    McLaurin J, Cecal R, Kierstead ME et al (2002) Therapeutically effective antibodies against amyloid-beta peptide target amyloid-beta residues 4–10 and inhibit cytotoxicity and fibrillogenesis. Nat Med 8:1263–1269PubMedCrossRefGoogle Scholar
  16. 16.
    Moretto N, Bolchi A, Rivetti C et al (2007) Conformation-sensitive antibodies against Alzheimer amyloid-beta by immunization with a thioredoxin-constrained B-cell epitope peptide. J Biol Chem 282:11436–11445PubMedCrossRefGoogle Scholar
  17. 17.
    Frenkel D, Kariv N, Solomon B (2001) Generation of auto-antibodies towards Alzheimer’s disease vaccination. Vaccine 19:2615–2619PubMedCrossRefGoogle Scholar
  18. 18.
    Zou J, Yao Z, Zhang G et al (2008) Vaccination of Alzheimer’s model mice with adenovirus vector containing quadrivalent foldable Aβ1–15 reduces Aβ burden and behavioral impairment without Aβ-specific T cell response. J Neurol Sci 272:87–98PubMedCrossRefGoogle Scholar
  19. 19.
    Donnelly JJ, Liu MA, Ulmer JB (2000) Antigen presentation and DNA vaccines. Am J Respir Crit Care Med 162:S190–S193PubMedGoogle Scholar
  20. 20.
    Boyer JL, Kobinger G, Wilson JM et al (2005) Adenovirus-based genetic vaccines for biodefense. Hum Gene Ther 16:157–168PubMedCrossRefGoogle Scholar
  21. 21.
    Kim HD, Kong FK, Cao Y et al (2004) Immunization of Alzheimer model mice with adenovirus vectors encoding amyloid beta-protein and GM-CSF reduces amyloid load in the brain. Neurosci Lett 370:218–223PubMedCrossRefGoogle Scholar
  22. 22.
    Zhang J, Wu X, Qin C et al (2003) A novel recombinant adeno-associated virus vaccine reduces behavioral impairment and β-amyloid plaques in a mouse model of Alzheimer’s disease. Neurobiol Dis 14:365–379PubMedCrossRefGoogle Scholar
  23. 23.
    Otten G, Schaefer M, Doe B et al (2004) Enhancement of DNA vaccine potency in rhesus macaques by electroporation. Vaccine 22:2489–2493PubMedCrossRefGoogle Scholar
  24. 24.
    Aihara H, Miyazaki J (1998) Gene transfer into muscle by electroporation in vivo. Nat Biotechnol 16:867–870PubMedCrossRefGoogle Scholar
  25. 25.
    Schenk D, Barbour R, Dunn W (1999) Immunization with amyloid-beta attenuates Alzheimer-disease-like pathology in the PDAPP mouse. Nature 400:173–177PubMedCrossRefGoogle Scholar
  26. 26.
    Wang CY, Wang T, Zheng W et al (2010) Zinc overload enhances APP cleavage and Aβ deposition in the Alzheimer mouse brain. PLoS ONE 5:e15349PubMedCrossRefGoogle Scholar
  27. 27.
    Holmes C, Boche D, Wilkinson D et al (2008) Long-term effects of Aβ42 immunisation in Alzheimer’s disease: follow-up of a randomised, placebo-controlled phase I trial. Lancet 372:216–223PubMedCrossRefGoogle Scholar
  28. 28.
    St. George-Hyslop PH, Morris JC (2008) Will anti-amyloid therapies work for Alzheimer’s disease? Lancet 372:180–182PubMedCrossRefGoogle Scholar
  29. 29.
    Finocchiaro LM, Nahmod VE, Launay JM (1991) Melatonin biosynthesis and metabolism in peripheral blood mononuclear leucocytes. Biochem J 280:727–731PubMedGoogle Scholar
  30. 30.
    Hellstrand K, Hermodsson S (1990) Monocyte-mediated suppression of IL-2-induced NK-cell activation: regulation by 5-HT1-type serotonin receptors. Scand J Immunol 32:183–192PubMedCrossRefGoogle Scholar
  31. 31.
    Shaji AV, Kulkarni SK, Agrewala JN (1998) Regulation of secretion of IL-4 and IgG1 isotype by melatonin-stimulated ovalbumin-specific T cells. Clin Exp Immunol 111:181–185PubMedCrossRefGoogle Scholar
  32. 32.
    Reiter RJ, Cabrera J, Sainz RM et al (1999) Melatonin as a pharmacological agent against neuronal loss in experimental models of Huntington’s disease, Alzheimer’s disease and parkinsonism. Ann NY Acad Sci 890:471–485PubMedCrossRefGoogle Scholar
  33. 33.
    Connor TP (2008) Melatonin as an adjuvant to therapeutic prostate cancer vaccines. J Pineal Res 45:224PubMedCrossRefGoogle Scholar
  34. 34.
    Lambracht-Washington D, Qu BX, Fu M et al (2009) DNA beta-amyloid(1–42) trimer immunization for Alzheimer disease in a wild-type mouse model. JAMA 302:1796–1802PubMedCrossRefGoogle Scholar
  35. 35.
    Torres KC, Dutra WO, Gollob KJ (2004) Endogenous IL-4 and IFN-gamma are essential for expression of Th2, but not Th1 cytokine message during the early differentiation of human CD4+ T helper cells. Hum Immunol 65:1328–1335PubMedCrossRefGoogle Scholar
  36. 36.
    Wang YJ, Pollard A, Zhong JH et al (2009) Intramuscular delivery of a single chain antibody gene reduces brain Abeta burden in a mouse model of Alzheimer’s disease. Neurobiol Aging 30:364–376PubMedCrossRefGoogle Scholar
  37. 37.
    Janus C, Pearson J, McLaurin J et al (2000) A beta peptide immunization reduces behavioural impairment and plaques in a model of Alzheimer’s disease. Nature 408:979–982PubMedCrossRefGoogle Scholar
  38. 38.
    Wilcock DM, Munireddy SK, Rosenthal A et al (2004) Microglial activation facilitates Abeta plaque removal following intracranial anti-Abeta antibody administration. Neurobiol Dis 15:11–20PubMedCrossRefGoogle Scholar
  39. 39.
    DeMattos RB, Bales KR, Cummins DJ et al (2001) Peripheral anti-A beta antibody alters CNS and plasma A beta clearance and decreases brain A beta burden in a mouse model of Alzheimer’s disease. Proc Natl Acad Sci U S A 98:8850–8855PubMedCrossRefGoogle Scholar
  40. 40.
    Solomon B, Koppel R, Frankel D et al (1997) Disaggregation of Alzheimer beta-amyloid by site-directed mAb. Proc Natl Acad Sci U S A 94:4109–4112PubMedCrossRefGoogle Scholar
  41. 41.
    Dong Y, Benveniste EN (2001) Immune function of astrocytes. Glia 36:180–190PubMedCrossRefGoogle Scholar

Copyright information

© Springer Science+Business Media, LLC 2012

Authors and Affiliations

  • Sha Sha
    • 1
  • Xiao-Na Xing
    • 1
  • Wan-Shu Guo
    • 2
  • Yu Li
    • 1
  • Li-Xia Zong
    • 1
  • Rong Guo
    • 3
  • Yun-Peng Cao
    • 1
  1. 1.Department of NeurologyFirst Affiliated Hospital of China Medical UniversityShenyangChina
  2. 2.Department of NeurologySecond Affiliated Hospital of Shenyang Medical UniversityShenyangChina
  3. 3.Department of NeurologyThe People’s Hospital of Liaoning ProvinceShenyangChina

Personalised recommendations